Asia Pacific Next-generation Antibody Market : Table of Contents

1. Introduction

1.1 Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Data Triangulation and Validation

4. Asia Pacific Next-generation Antibody Market Landscape

4.1 Overview

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. Asia Pacific Next-generation Antibody Market – Key Market Dynamics

5.1 Market Drivers

5.2 Market Restraints

5.3 Market Opportunities

5.4 Future Trends

5.5 Impact of Drivers and Restraints

6. Asia Pacific Next-generation Antibody Market Regional Analysis

6.2 Asia Pacific Next-generation Antibody Market Revenue 2019-2028 (US$ Million)

6.3 Asia Pacific Next-generation Antibody Market Forecast Analysis

7. Asia Pacific Next-generation Antibody Market Analysis – by Therapeutic Area

7.1 Oncology

7.1.1 Overview
7.1.2 Oncology: Asia Pacific Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)

7.2 Autoimmune or Inflammatory

7.2.1 Overview
7.2.2 Autoimmune or Inflammatory: Asia Pacific Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)

8. Asia Pacific Next-generation Antibody Market Analysis – by Technology

8.1 Antibody-drug conjugates

8.1.1 Overview
8.1.2 Antibody-drug conjugates: Asia Pacific Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)

8.2 Bispecific antibodies

8.2.1 Overview
8.2.2 Bispecific antibodies: Asia Pacific Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)

8.3 Fc engineered antibodies

8.3.1 Overview
8.3.2 Fc engineered antibodies: Asia Pacific Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)

8.4 Antibody fragments & antibody-like proteins

8.4.1 Overview
8.4.2 Antibody fragments & antibody-like proteins: Asia Pacific Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)

8.5 Biosimilar antibody products

8.5.1 Overview
8.5.2 Biosimilar antibody products : Asia Pacific Next-generation Antibody Market – Revenue and Forecast, 2019-2028 (US$ Million)

9. Asia Pacific Next-generation Antibody Market – Asia-Pacific Analysis

9.1 Overview

9.2 Asia-Pacific

9.2.1 Asia Pacific Next-generation Antibody Market Breakdown, by Key Country, 2022 and 2028 (%)
9.2.1.1 Asia Pacific Next-generation Antibody Market – Revenue and Forecast Analysis – by Country
9.2.1.1 China: Asia Pacific Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.1.1.1 China: Asia Pacific Next-generation Antibody Market Breakdown, by Therapeutic Area
9.2.1.1.2 China: Asia Pacific Next-generation Antibody Market Breakdown, by Technology

9.2.1.2 India: Asia Pacific Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.1.2.1 India: Asia Pacific Next-generation Antibody Market Breakdown, by Therapeutic Area
9.2.1.2.2 India: Asia Pacific Next-generation Antibody Market Breakdown, by Technology

9.2.1.3 Japan: Asia Pacific Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.1.3.1 Japan: Asia Pacific Next-generation Antibody Market Breakdown, by Therapeutic Area
9.2.1.3.2 Japan: Asia Pacific Next-generation Antibody Market Breakdown, by Technology

9.2.1.4 Australia: Asia Pacific Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.1.4.1 Australia: Asia Pacific Next-generation Antibody Market Breakdown, by Therapeutic Area
9.2.1.4.2 Australia: Asia Pacific Next-generation Antibody Market Breakdown, by Technology

9.2.1.5 Rest of Asia-Pacific : Asia Pacific Next-generation Antibody Market – Revenue and Forecast to 2028 (US$ Million)

9.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Next-generation Antibody Market Breakdown, by Therapeutic Area
9.2.1.5.2 Rest of Asia-Pacific : Asia Pacific Next-generation Antibody Market Breakdown, by Technology

10. Competitive Landscape

10.1 Heat Map Analysis

10.2 Company Positioning and Concentration

11. Industry Landscape

11.1 Overview

11.2 Market Initiative

11.3 Partnerships and Collaborations

11.4 Other Developments

12. Company Profiles

12.1 F. HOFFMANN-LA ROCHE LTD.

12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments

12.2 Kyowa Kirin Co., Ltd.

12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments

12.3 Seagen Inc.

12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments

12.4 Takeda Pharmaceutical Company Limited

12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments

12.5 Amgen Inc.

12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments

12.6 Pfizer Inc.

12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments

12.7 Catalent Inc

12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments

12.8 AstraZeneca

12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments

13. Appendix

13.1 About Business Market Insights

13.2 List of Abbreviations

Asia Pacific Next-generation Antibody Market

Analysis By Therapeutic Area (Oncology, and Autoimmune or Inflammatory) and Technology (Antibody-drug conjugates, Bispecific antibodies, Fc engineered antibodies, Antibody fragments & antibody-like proteins, and Biosimilar antibody products)